TY - JOUR T1 - Dysregulation of the Arachidonic Acid Pathway in Cystic Fibrosis: Implications for Chronic Inflammation and Disease Progression. AU - D'Orazio,Simona, AU - Mattoscio,Domenico, Y1 - 2024/09/09/ PY - 2024/07/09/received PY - 2024/08/29/revised PY - 2024/08/31/accepted PY - 2024/9/28/medline PY - 2024/9/28/pubmed PY - 2024/9/28/entrez KW - CFTR KW - DHA KW - arachidonic acid KW - cyclooxygenases KW - cystic fibrosis KW - eicosanoids KW - leukotrienes KW - lipid peroxidation KW - lipoxygenases KW - prostaglandins JF - Pharmaceuticals (Basel, Switzerland) JO - Pharmaceuticals (Basel) VL - 17 IS - 9 N2 - Cystic fibrosis (CF) is the most common fatal genetic disease among Caucasian people, with over 2000 mutations in the CFTR gene. Although highly effective modulators have been developed to rescue the mutant CFTR protein, unresolved inflammation and persistent infections still threaten the lives of patients. While the central role of arachidonic acid (AA) and its metabolites in the inflammatory response is widely recognized, less is known about their impact on immunomodulation and metabolic implications in CF. To this end, here we provided a comprehensive analysis of the AA metabolism in CF. In this context, CFTR dysfunction appeared to complexly disrupt normal lipid processing, worsening the chronic airway inflammation, and compromising the immune responses to bacterial infections. As such, potential strategies targeting AA and its inflammatory mediators are being investigated as a promising approach to balance the inflammatory response while mitigating disease progression. Thus, a deeper understanding of the AA pathway dysfunction in CF may open innovative avenues for designing more effective therapeutic interventions. SN - 1424-8247 UR - https://www.unboundmedicine.com/medline/citation/39338347/full_citation DB - PRIME DP - Unbound Medicine ER -